Agenda for the IAEN Pre-Conference Meeting in Cuernavaca, Mexico
| Type | Conferences |
|---|---|
| Posted | 06/13/2008
|
| Contact | |
| Description | International AIDS Economics Network: Pre-Conference Meeting Instituto Nacional de Salud Pública Avenida Universidad 655 Cuernavaca, Morelos, México
Friday 1st August 2008
8:45 – 9:00 Welcome to INSP Mario Henry Rodriguez Lopéz, Director General del Instituto Nacional de Salud Pública (INSP)
9:00 - 9:20 Welcome to International AIDS and Economics Network (IAEN) Steven Forsythe, Acting President, IAEN
9:20 – 9:50 Keynote speech: How to Make the Global HIV Response Sustainable
9:50 – 10:00 Coffee break
10:00 – 11:20 The Cost of ART Medications Chair: Eileen Stillwaggon, Gettysburg College Presentations: ☼ “HIV/AIDS Drug Treatment Costs at the Mexican Institute of Social Security,” Rodrigo Medinilla, Universidad Autónoma de Chihuahua, México. ☼ “Getting people to pills: transport costs, socio economic status and reasons for defaulting from ART in public sector clinics in South Africa,” Gesine Meyer Rath, University of the Witwatersrand, South Africa and LSHTM, UK. ☼ “The Costs of AIDS Treatment in South Africa,” Rory Leisegang, University of Cape Town. Discussant: Rob Hecht, Results for Development Institute
11:20 – 12:40 Economics and Behavior Change Chair: Robert Greener, UNAIDS Presentations: ☼ “Condom use and different types of capital among MSM in Mexico City,” Omar Galarraga, INSP, Mexico. ☼ “Who Gets AIDS and How? Education, HIV Infection and Sexual Behaviors,” Damien de Walque, World Bank, USA. ☼ ”Determinants of women's demand for microbicides: results from a discrete choice experiment in urban South Africa,” F. Terris-Prestholt, LSHTM, UK. Discussants: Alan Whiteside, HEARD
12:40 – 13:40 Lunch (catered)
13:40 – 14:40 The Economics of Scale Chair: Lilani Kumaranayake, LSHTM Presentations: ☼ “Human Immunodeficiency Virus Intervention Costs and Program Scale in Three Different Ecological Regions of Cameroon,” David Nkengafac, University of Buea, Cameroon. ☼ “The effects of scale on costs of targeted HIV prevention interventions among female and male sex workers, MSM and Transgenders in India.” S. Chandrashekar, Karnataka Health Promotion Trust India. Discussant: Hilary Southall, Joint Economics AIDS and Poverty Programme
14:40 – 15:00 Coffee
15:45 – 17:30 Assessing the Impact of HIV and AIDS Chair: John Fieno, Research Triangle Institute Presentations: ☼ “Antiretroviral Therapy and Impaired Presenteeism among Kenyan Agricultural Workers,” B.A. Larson, Boston University, USA. ☼ “The Macroeconomic Impact of HIV/AIDS on the KwaZulu Natal South Africa Economy and its People,” Jeff Gow, University of Southern Queensland, Australia. ☼ “The IMAGE study: a cluster-randomized controlled trial to measure the impact on domestic violence and HIV risk of a combined micro-finance and participatory,” Paul Pronyk, University of the Witwatersrand, South Africa and LSHTM, UK. ☼ “An institutional audit of the impact of HIV and AIDS on Malawi’s education sector, 2000-2003,” Sutapa Choudhury, University of Oxford, UK. Discussant: Gayle Martin, World Bank
Saturday 2nd August 2008
8:30 – 9:00 Coffee
9:00 - 9:20 Welcome to Instituto Nacional de Salud Pública (INSP) Stefano Bertozzi, INSP
9:20 – 9:50 Keynote speech: Innovations in Financing for Universal Protection against HIV/AIDS Julio Frenk, Gates Foundation and Grupo Carso Health Institute of Mexico
9:50 – 10:50 Resource Allocation and Expenditure Tracking Chair: John Stover, Futures Institute Presenters: ☼ “Supporting decision makers in costing and prioritising HIV/AIDS interventions - a tool to manage rather than ignore information uncertainty,” Julienne McKay, Instituto Centroamericano de la Salud, Nicaragua. ☼ “Coordinated HIV/AIDS expenditure tracking: the Rwandan example,” Agnés Binagwaho, National AIDS Control Commission, Rwanda. ☼ “Cost-Benefit Analysis of Global Fund HIV/AIDS Programming,” Lilani Kumaranayake, LSHTM, UK. Discussant: Jean-Paul Moatti, ANRS
11:50 – 13:30 Economic Evaluation, HIV and AIDS Chair: Antonieta Medina-Lara, LSTM Presentations: ☼ “The Cost effectiveness of Genotypic Antiretroviral Resistance Testing in HIV Infected Patients with Therapeutic Failure,” A.A. Adogafec, Institute of Research for Development, and University of Buea, Cameroon. ☼ “Cost-Effectiveness Analysis of Raltegravir in Treatment-Experienced HIV Patients in Spain,”Mohammad A. Chaudhary, Merck Research Laboratories, USA. ☼ “The Cost Effectiveness of Three Antiretroviral Treatment Interventions for HIV/AIDS Infected Patients,” Kakon Montua, University of Buea, South Western Cameroon. ☼ “Cost Effectiveness of different starting criteria of antiretroviral therapy in Mexico,” Y. Caro, INSP, Mexico. Discussant: Stefano Bertozzi, INSP
13:30 – 13:50 Sponsor presentations Jeffrey Sturchio (Merck) Robert Greener (UNAIDS) Alan Whiteside (HEARD) Stefano Bertozzi (INSP)
13:50 – 14:50 Lunch
14:50 – 15:20 Poster Sessions
15:20 – 16:20 Antiretroviral Therapy
Chair: Jeffrey Sturchio, Merck Presentations: ☼ “Stable patient outcomes and outpatient costs in South African patients second year on antiretroviral treatment,” Lawrence Long, Wits Health Consortium, South Africa. ☼ “Ranking Government commitment to providing antiretroviral treatment using cross-country regression analysis,” N. Nattrass, University of Cape Town, South Africa. Discussant: Jeff Gow, HEARD
16:20 – 16:40 Tea
16:40 – 17:30 IAEN business and closure |